Pfizer’s Kindler gets it
If you don’t have a chance to view the slides or watch the videocast of yesterday’s Pfizer meeting outlining its plans for the near-future, you should check out BusinessWeek’s coverage of the analyst event for a nice summary. One reason to pay attention: Pfizer is the world’s largest pharmaceutical firm, so their actions influence the entire industry. A better reason: Mr. Kindler’s succintly summarized, coherent vision for Pfizer is a response to forces affecting all companies making innovative drugs, biological and small-molecule both. Pfizer’s moves may be opening up windows of opportunity for other companies who’ve been waiting for it to blink, but eventually all companies of a certain size will be compelled to make similar changes in their operations and approach to the marketplace. Small firms and their investors should take note too; it’s a seller’s market for your technology and is likely to remain so for the forseeable future.
